Observational studyThe Journal of dermatology2026
Treatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims-Based Study.
Observational study in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co-occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern. However, real-world data on treatment patterns and the economic burden of AD in children remain sparse. This retrospective observational study aimed to assess the clinical profiles of pediatric patients with AD using data from the JMDC Claims database. Children aged 0-6 years diagnosed with AD between January 2018 and September 2023 were included. A total of 244 316 children with AD (mean age: 3.1 years; 51.3% male) were included. Of these, 17.7% had AD-only, and 82.3% had AD with ACM. Allergic rhinitis was the most prevalent ACM. Topical corticosteroids were the most prescribed treatment, with 94.0% of patients with ACMs and 85.5% of those with AD-only receiving them. Potent corticosteroids were more frequently used in the AD with ACM group. Systemic steroids (31.5% vs. 4.8%) and antihistamines (95.5% vs. 56.1%) were used more often in the AD with ACMs group than in the AD-only group. Patients in the AD with ACM versus AD-only group had more outpatient visits (11.1/year vs. 6.5/year) and comparable hospitalization frequency, but shorter hospital stays (2.4 vs. 7.7 days per year). Median annual healthcare costs were substantially higher in the AD with ACM group compared to the AD-only group (139 391 Yen vs. 98 646 Yen), with costs increasing as the number of ACMs increased. Notably, 84.7% of patients with three ACMs incurred annual healthcare costs exceeding 100 000 Yen. These findings highlighted the increased clinical and economic burden associated with the increasing number of ACMs in children with AD, emphasizing the need for more intensive treatment and healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.